Loss of p21(waf1) expression is a strong predictor of reduced survival in primary superficial bladder cancers

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3131-3138

  Migaldi, Mario ^a   Sgambato, Alessandro ^b   Garagnani, Lorella ^a   Ardito, Raffaele ^b   Ferrari, Paolo ^b   De Gaetani, Carmela ^a   Cittadini, Achille ^b   Trentini, Gian Paolo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION FUNCTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SUPERFICIAL CANCER; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; BLADDER TUMOR; CANCER STAGING; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0033624177     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Orlow, I., Lacombe, L., Hannon, G. J., Serrano, M., Pellicer, I., Dalbagni, G., Reuter, V. E., Zhang, Z-F., Beach, D., and Cordon-Cardo, C. Deletion of the p16 and p15 genes in human bladder tumors. J. Natl. Cancer Inst., 87: 1524-1529, 1995.
2. Shin, K. Y., Kong, G., Kim, W. S., Lee, T. Y., Woo, Y. N., and Lee, J. D. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br. J. Cancer, 75: 1788-1792, 1997.
3. Cote, R. J., Dunn, M. D., Chatterjee, S. J., Stein, J. P., Shi, S-R., Tran, Q-C., Hu, S. X., Xu, H. J., Groshen, S., Taylor, C. R., Skinner, D. G., and Benedict, W. F. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res., 58: 1090-1094, 1998.
4. Lipponen, P. K. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365-370, 1993.
5. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W., and Reuter, V. E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53-59, 1993.
6. Serth, J., Kuczyk, M. A., Bokemeyer, C., Hervatin, C., Nafe, R., Tan, H. K., and Jonas, U. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br. J. Cancer, 71: 201-205, 1995.
7. Zlotta, A. R., Noel, J. C., Fayt, I., Drowart, A., Van Vooren, J. P., Huygen, K., Simon, J., and Schulman, C. C. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guérin intravesical therapy. J. Urol., 161: 792-798, 1999.
8. Lipponen, P., Aaltomaa, S., Eskelinen, M., Ala-Opas, M., and Kosma, V-M. Expression of p21(wafl/cipl) protein in transitional cell bladder tumours and its prognostic value. Eur. Urol., 34: 237-243, 1998.
9. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., and Cote, R. J. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 90: 1072-1079, 1998.
10. Osen, I., Fossa, S. D., Majak, B., Rotterud, R., and Berner, A. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. Br. J. Urol., 81: 862-869, 1998.
11. Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res., 59: 3245-3250, 1999.
12. Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J., Wilczynski, S., Lee, Y. Y., Bartram, C. R., and Koeffler, H. P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip 1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.
13. Kip 1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55: 1211-1214, 1995.
14. Shiohara, M., El-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D-L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
15. Malkowicz, S. B., Tomaszewski, J. E., Linnenbach, A. J., Cangiano, T. A., Maruta, Y., and McGarvey, T. W. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene, 13: 1831-1837, 1996.
16. Lacombe, L., Orlow, I., Silver, D., Gerald, W. L., Fair, W. R., Reuter, V. E., and Cordon-Cardo, C. Analysis of p21WAF1/CIP1 in primary bladder tumors. Oncol. Res., 8: 409-414, 1996.
17. WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82: 675-684, 1995.
18. Kip1-deficient mice. Cell, 85: 733-744, 1996.
19. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
20. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
21. Esrig, D., Spruck, C. H., Nichols, P., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A., and Cote, R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am. J. Pathol., 143: 1389-1397, 1993.
22. El-Deiry, W., Tokino, T., Waldman, T., Oliner, J. D., Velculescu, V. E., Burrell, M., Hill, D. E., Healy, E., Rees, J. L., Hamilton, S. R., Kinzler, K. W., and Vogelstein, B. Topological control of p21 waf1/ Cip1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1995.
23. Ogawa, M., Maeda, K., Onoda, N., Chung, Y-S., and Sowa, M. Loss of p21Waf1/Cip1 expression correlates with disease progression in gastric carcinoma. Br. J. Cancer, 75: 1617-1620, 1997.
24. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res., 2: 1591-1599, 1996.
25. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of Waf1/Cip1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
26. Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W., and Elledge, S. J. p53-independent expression of p21CIP1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
27. Barboule, N., Mazars, P., Baldin, V., Vidal, S., Jozan. S., Martel, P., and Valette, A. Expression of p21IWAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian cancers. Int. J. Cancer, 63: 611-615, 1995.
28. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Bertacca, G., Chella, A., Merlo, G., Angeletti, C. A., Dalla Palma, P., and Bevilacqua, G. p21 RNA, and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene, 12: 1319-1324, 1996.
29. Barboule, N., Baldin, V., Jozan, S., Vidal, S., and Valette, A. Increased level of p21 in human ovarian tumors is associated with increased expression of CDK2, cyclin A and PCNA. Int. J. Cancer. 76: 891-896, 1998.
30. Cip1 in human brain tumors Oncogene, 11: 2021-2028, 1995.
31. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
32. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-233, 1997.
33. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
34. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell-cycle regulators p27 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
35. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542-548, 1998.
36. Mostofi, F. H., Sobin, L. H., and Torloni, H. Histological typing of urinary bladder tumours. In: International Classification of Tumours, Ed. 10. Geneva: WHO, 1973.
37. Sobin, L. H., and Wittekind, C. TNM Classification of Malignant Tumours, Ed. 5. New York: Wiley-Liss, 1997.
38. Barbareschi, M., Caffo, O., Doglioni, C., Fina, P., Marchetti, A., Buttitta, F., Leek, R., Morelli, L., Leonardi, E., Bevilacqua, G., Dalla Palma, P., and Harris, A. L. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer, 74: 208-215, 1996.
39. Backe, J., Gassel, A. M., Hauber, K., Krebs, S., Bartek, J., Caffier, H., Kreipe, H-H., Muller-Hermelink, H-K., and Dietl, J. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int. J. Gynecol. Pathol., 16: 361-365, 1997.
40. Clasen, S., Schulz, W. A., Gerharz, C-D., Grimm, M-O., Christoph, F., and Schmitz-Drager, B. J. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br. J. Cancer, 77: 515-521, 1999.
41. Gardiner, R. A., Walsh, M. D., Allen, V., Rahman, S., Samaratunga, M. L. T. H., Seymour, G. J., and Lavin, M. F. Immunohistological expression of p53 in primary pTl transitional cell bladder cancer in relation to tumour progression. Br. J. Urol., 73: 526-532, 1994.
42. Nakopoulou, L., Constantinides, C., Papandropoulos, J., Theodoropoulos, G., Tzonou, A., Giannopoulos, A., Zervas, A., and Dimopoulos, C. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology, 46: 334-340, 1995.
43. Kip 1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci., USA, 94: 6380-6385, 1997.
44. Kip 1 in human breast cancers. Clin. Cancer Res., 3: 1879-1887, 1997.
45. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 26: 1237-1245, 1992.
46. Schmitz-Drager, B. J., Kushima, M., Goebell, P., Jax, T. W., Gerharz, C-D., Bultel, H., Schulz, W. A., Ebert, T., and Ackermann, R. p53 and MDM2 in the development and progression of bladder cancer. Eur. Urol., 32: 487-493, 1997.
47. Lianes, P., Orlow, I., Zhang, Z-F., Oliva, M. R., Sarkis, A. R., Reuter, V. E., and Cordon-Cardo, C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst., 86: 1325-1330, 1994.
48. Haffner, R., and Oren, M. Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev., 5: 84-90, 1995.